Sio Gene Therapies Inc. (SIOX) Stock Analysis
DELISTED 2024
What happened to Sio Gene Therapies Inc. (SIOX) stock?
Sio Gene Therapies Inc. (SIOX) no longer trades on public markets. It was delisted in February 2024. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sio Gene Therapies Inc. (SIOX) trades at $0.478. Sio Gene Therapies Inc. is a clinical-stage biotechnology company focused on developing gene therapies for neurodegenerative diseases. Their pipeline includes programs targeting GM1 gangliosidosis and Parkinson's disease. Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for SIOX: SIOX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SIOX against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
SIOX: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Sio Gene Therapies Inc. (SIOX) Healthcare & Pipeline Overview
Sio Gene Therapies Inc. is a clinical-stage biotech firm specializing in gene therapies for neurodegenerative disorders, including GM1 gangliosidosis and Parkinson's disease. The company leverages licensing agreements with Oxford BioMedica and the University of Massachusetts Medical School to advance its pipeline and address unmet medical needs in the healthcare sector.
What Is the Investment Thesis for SIOX?
Sio Gene Therapies presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on gene therapies for neurodegenerative diseases, particularly GM1 gangliosidosis and Parkinson's disease, addresses areas of significant unmet medical need. Key value drivers include the successful advancement of AXO-AAV-GM1 and AXO-Lenti-PD through clinical trials, demonstrating safety and efficacy. Upcoming data readouts from ongoing clinical studies will serve as major catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional capital to fund ongoing research and development. The company's negative P/E ratio of -0.49 reflects its current lack of profitability, typical for clinical-stage biotech companies.
Based on FMP financials and quantitative analysis
SIOX Key Highlights
Focus on gene therapies for neurodegenerative diseases addresses a significant unmet medical need.
- Strategic licensing agreements with Oxford BioMedica and the University of Massachusetts Medical School provide access to key technologies and expertise.
- AXO-AAV-GM1 and AXO-Lenti-PD are the lead product candidates targeting GM1 gangliosidosis and Parkinson's disease, respectively.
- Clinical-stage development represents a high-risk, high-reward profile with potential for significant value creation upon successful clinical trial outcomes.
- Relatively small employee base of 12 indicates a lean operational structure.
Who Are SIOX's Competitors?
SIOX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| FRLN Freeline Therapeutics Holdings plc | $6.49 | +0.15% | $28.3M | 44 |
| GRCE Grace Therapeutics, Inc. | $2.14 | -2.73% | $34.8M | 49 |
| IRD Opus Genetics, Inc. | $4.12 | +1.23% | $340M | — |
| LMNL Liminal BioSciences Inc. | $8.50 | +0.12% | $27.6M | 50 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SIOX's Key Strengths?
Focus on gene therapies for neurodegenerative diseases.
- Strategic licensing agreements with Oxford BioMedica and the University of Massachusetts Medical School.
- Potential for high pricing and limited competition in rare disease markets.
- Lean operational structure with a small employee base.
What Are SIOX's Weaknesses?
Clinical-stage company with no approved products.
- Reliance on external partnerships for technology and expertise.
- High cash burn rate and need for additional funding.
- Negative P/E ratio reflects current lack of profitability.
What Could Drive SIOX Stock Higher?
Data readouts from ongoing clinical trials of AXO-AAV-GM1 for GM1 gangliosidosis.
- Data readouts from ongoing clinical trials of AXO-Lenti-PD for Parkinson's disease.
- Potential for new strategic partnerships to expand the pipeline.
- Progress in securing orphan drug designation for lead programs.
What Are the Key Risks for SIOX?
Financial-distress signal — its Altman Z-Score of -17.26 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-78.3%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for AXO-AAV-GM1 and AXO-Lenti-PD.
- Regulatory hurdles and delays in obtaining marketing approval.
- Competition from other gene therapy companies.
- Difficulty in raising additional capital to fund ongoing research and development.
What Are the Growth Opportunities for SIOX?
- Advancement of AXO-AAV-GM1 for GM1 Gangliosidosis: GM1 gangliosidosis is a rare and fatal neurodegenerative disease with no approved treatments. Successful clinical development and regulatory approval of AXO-AAV-GM1 could provide a significant growth opportunity for Sio Gene Therapies. The market for rare disease therapies is substantial, with potential for high pricing and limited competition. Timeline for potential approval is estimated within the next 3-5 years, pending successful clinical trial outcomes.
- Development of AXO-Lenti-PD for Parkinson's Disease: Parkinson's disease is a common neurodegenerative disorder affecting millions worldwide. AXO-Lenti-PD represents a potential disease-modifying therapy for Parkinson's disease, addressing a large and underserved market. Success in clinical trials could lead to significant commercial opportunities for Sio Gene Therapies. The timeline for potential approval is estimated within the next 5-7 years, contingent on positive clinical data and regulatory review.
- Expansion of Pipeline through Strategic Partnerships: Sio Gene Therapies can expand its pipeline by entering into additional licensing agreements or collaborations with academic institutions and other biotechnology companies. This would allow the company to access new technologies and therapeutic targets, diversifying its portfolio and reducing risk. The timeline for pipeline expansion is ongoing, with potential for new partnerships to be established in the near future.
- Securing Orphan Drug Designation for Lead Programs: Orphan drug designation provides several benefits, including market exclusivity, tax credits, and reduced regulatory fees. Sio Gene Therapies can pursue orphan drug designation for its lead programs, enhancing their commercial potential and attractiveness to potential partners. The timeline for securing orphan drug designation is typically within 1-2 years of initiating clinical trials.
- Out-licensing or Acquisition by a Larger Pharmaceutical Company: Sio Gene Therapies could pursue an out-licensing strategy, partnering with a larger pharmaceutical company to develop and commercialize its gene therapy programs. Alternatively, the company could be acquired by a larger pharmaceutical company seeking to expand its gene therapy portfolio. These scenarios would provide significant returns for investors. The timeline for potential out-licensing or acquisition is uncertain but could occur within the next 3-5 years, depending on clinical trial progress and market conditions.
What Are SIOX's Competitive Advantages?
- Proprietary gene therapy technologies.
- Intellectual property protection for lead product candidates.
- Expertise in developing gene therapies for rare diseases.
- Strategic partnerships with leading research institutions.
What Does SIOX Do?
Sio Gene Therapies Inc., formerly known as Axovant Gene Therapies Ltd., is a clinical-stage biotechnology company dedicated to developing innovative gene therapies for patients suffering from neurodegenerative diseases. Incorporated in 2014 and based in New York City, the company focuses on transforming the lives of individuals affected by debilitating conditions with limited treatment options. Sio Gene Therapies leverages strategic licensing agreements to bolster its research and development efforts. A key agreement with Oxford BioMedica (UK) Ltd. enables the development and commercialization of AXO-Lenti-PD and related gene therapy products targeting Parkinson's disease. Additionally, a collaboration with The University of Massachusetts Medical School supports the development of gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM2, aimed at treating GM1 and GM2 gangliosidosis, respectively. The company's pipeline represents a commitment to addressing significant unmet medical needs in the field of neurodegenerative disorders, with a focus on advancing novel gene therapy approaches from preclinical stages through clinical development.
What Products and Services Does SIOX Offer?
- Develop gene therapies for neurodegenerative diseases.
- Focus on transforming the lives of patients with limited treatment options.
- Target rare diseases like GM1 gangliosidosis.
- Develop therapies for more common diseases like Parkinson's disease.
- Utilize licensing agreements with research institutions and other companies.
- Advance gene therapy candidates through preclinical and clinical development.
How Does SIOX Make Money?
- Develop and commercialize gene therapies for neurodegenerative diseases.
- Generate revenue through potential out-licensing agreements or partnerships.
- Seek regulatory approval for gene therapy products to generate future sales.
What Industry Does SIOX Operate In?
Sio Gene Therapies operates within the competitive biotechnology industry, specifically focusing on gene therapy. The gene therapy market is experiencing rapid growth, driven by technological advancements and increasing success in clinical trials. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms developing gene therapies for various diseases. Sio Gene Therapies differentiates itself by focusing on rare neurodegenerative diseases with limited treatment options. The company's success depends on its ability to navigate regulatory hurdles, secure funding, and demonstrate clinical efficacy.
Who Are SIOX's Key Customers?
- Patients suffering from neurodegenerative diseases.
- Healthcare providers who treat patients with these conditions.
- Potential pharmaceutical partners interested in licensing or acquiring gene therapy programs.
Financial Health
Sio Gene Therapies Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -17.26 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Sio Gene Therapies Inc. stands at -78.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -95.7%, showing how much profit it generates from its asset base. A current ratio of 5.52 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Sio Gene Therapies Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO David W. Nassif. SIOX has traded publicly since 2015.
SIOX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, which often signals a positive outlook to the market.
- Community sentiment has shifted positively, with discussions highlighting potential breakthroughs in gene therapy that could position Sio Gene Therapies as a leader in the field.
- Analysts have noted increasing interest in the company's pipeline, particularly its advancements in rare genetic disorders, which could attract significant investment.
- Recent collaborations with established biotech firms have bolstered the company's credibility and created optimism around upcoming product launches.
Bear Case
- Despite the positive sentiment, there are concerns regarding the competitive landscape in gene therapies, with larger players potentially overshadowing Sio's offerings.
- Some community members express skepticism about the timeline for product approvals, fearing delays could hinder growth and investor confidence.
- The company's financial health remains a topic of debate, with ongoing discussions about funding and cash flow that could impact operational capabilities.
- Market perception has been cautious, as broader economic factors and regulatory scrutiny in the biotech sector could pose risks to Sio's growth trajectory.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SIOX Latest News
No recent news available for SIOX.
Leadership: David W. Nassif
Unknown
Information about David W. Nassif's background is not available in the provided data. Therefore, a detailed biography cannot be provided.
Track Record: Information about David W. Nassif's track record is not available in the provided data. Therefore, key achievements and strategic decisions under his leadership cannot be provided.
What Investors Ask About Sio Gene Therapies Inc. (SIOX) — Healthcare
What happened to Sio Gene Therapies Inc. (SIOX) stock?
Sio Gene Therapies Inc. (SIOX) no longer trades on public markets. It was delisted in February 2024. The figures below are historical and are not a current quote.
Can I still buy SIOX shares?
No. SIOX stopped trading on public markets in February 2024, so the shares are not available through a broker. Anything you see quoted for SIOX elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before SIOX stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Sio Gene Therapies Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Sio Gene Therapies Inc. do?
Sio Gene Therapies Inc. is a clinical-stage biotechnology company focused on developing gene therapies for neurodegenerative diseases. The company's pipeline includes programs targeting GM1 gangliosidosis and Parkinson's disease. Sio Gene Therapies leverages licensing agreements with Oxford BioMedica and the University of Massachusetts Medical School to advance its pipeline and address unmet medical needs in the healthcare sector.
What are the main risks for SIOX?
As a clinical-stage biotechnology company, Sio Gene Therapies faces significant risks. Clinical trial failures represent a major concern, as the company's lead product candidates may not demonstrate safety or efficacy in clinical studies. Regulatory hurdles and delays could also impede the progress of its programs. Competition from other gene therapy companies is another risk factor.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.